Evidence map›Paper›PMID 35986522›Full record

ArticleCurrent topics in medicinal chemistry2022

Pharmacological Activities of the Genus

Ana Ediléia Barbosa Pereira Leal, Érica Martins de Lavor, Jackson de Menezes Barbosa, Maria Taís de Moura Fontes Araújo, Cristiane Dos Santos Cerqueira Alves, Raimundo Gonçalves de Oliveira Júnior, Ádley Antonini Neves de Lima, Jackson Roberto Guedes da Silva Almeida

Abstract read
PubMed Publisher
In one paragraph

Article in Current topics in medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Metabolic Profile of Leaves and Pulp ofPlants (Basel, Switzerland) · 2024
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ana Ediléia Barbosa Pereira LealPostgraduate Program in Biotechnology, State University of Feira de Santana, Feira de Santana, Brazil.ORCID 0000-0001-6594-8490
Érica Martins de LavorPostgraduate Program in Biotechnology, State University of Feira de Santana, Feira de Santana, Brazil.ORCID 0000-0003-1288-554X
Jackson de Menezes BarbosaCenter for Studies and Research of Medicinal Plants, Federal University of San Francisco Valley, Petrolina, Brazil.ORCID 0000-0001-9724-8034
Maria Taís de Moura Fontes AraújoCenter for Studies and Research of Medicinal Plants, Federal University of San Francisco Valley, Petrolina, Brazil.ORCID 0000-0001-6378-906X
Cristiane Dos Santos Cerqueira AlvesCenter for Studies and Research of Medicinal Plants, Federal University of San Francisco Valley, Petrolina, Brazil.ORCID 0000-0002-8282-9239
Raimundo Gonçalves de Oliveira JúniorCenter for Studies and Research of Medicinal Plants, Federal University of San Francisco Valley, Petrolina, Brazil.ORCID 0000-0002-9458-1744
Ádley Antonini Neves de LimaPostgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal, Brazil.
Jackson Roberto Guedes da Silva AlmeidaPostgraduate Program in Biotechnology, State University of Feira de Santana, Feira de Santana, Brazil.ORCID 0000-0002-0867-1357

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq 431566/2018-6, 307782/2017-4Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco - FACEPE APQ-0309-4.03/15
6 · The paper itself

Abstract

backgroundPassiflora L. is a genus belonging to the Passifloraceae family, with many species widely used in folk medicine and several pharmacological activities described in the scientific literature, being a major target for the development of new therapeutic products. Studies have identified several bioactive compounds in their composition as responsible for these activities, mainly C-glycoside flavonoids.

objectiveThe aim of this study was to carry out a review of patents related to the genus and its application in several pharmacological activities, important for the development of new drugs and formulations.

methodsThe search was carried out in 5 specialized databases, INPI, EPO, WIPO, Latipat and Derwent, using the term 'Passiflora' combined with 'A61K and A61P', subclasses of section A of the International Patent Classification (IPC), which are destined to medical, dental or hygienic purposes, and therapeutic activity of chemical compounds or medicinal preparation, respectively.

results1,198 patents citing the genus in the title or abstract have been found, 508 being duplicates. After exclusion and inclusion criteria, 23 patents written in English, Portuguese and Spanish were selected, which demonstrated biological assays in vivo with species of Passiflora as the only active constituent or incorporated in formulations with other compounds.

conclusionThe findings of this search showed growing interest in research and industrial areas in the pharmaceutical development with species of Passiflora, suggesting that the different bioactive compounds present in the genus can be considered as an important tool for the development of new effective and safe products with pharmacological potential.

Indexed as

Bioactive compoundsC-glycoside flavonoidsMedicinal plantsPassifloraPatentsPharmacological activity.

Identifiers

PMID35986522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.